Your English writing platform
Discover LudwigSuggestions(5)
Exact(3)
ICC in patients with massive bleeding was reduced by 45.64 %, ICD was less than normal at 59.32 %, MA was reduced by 88.15 %, IRCL was 86,16 % above the norm.
While major bleeding was reduced by 50%% with dabigatran compared with warfarin, it did not achieve statistical significance (p = 0.06).
In the subgroup of studies (14 studies, 10 260 patients) using intravenous enoxaparin, major bleeding was reduced by 34% compared with unfractionated heparin (0.66, 0.52 to 0.83; P<0.001, P for heterogeneity 0.9; absolute risk reduction 1.52%; NNT=66).
Similar(57)
The current article [ 1] mirrors a meta-analysis showing re-exploration for bleeding is reduced by aprotinin but not tranexamic acid in such patients [ 5].
The gate settings are found by minimising the artifacts introduced to the desirable component of the signal, whilst ensuring that the level of bleed is reduced by a certain amount.
In particular, a CES1 polymorphism significantly reduces the concentration of dabigatran in blood by 15%, and risk of bleeding was reduced of 33% [140].
In a retrospective study by Agerstrand et al., incidence of bleeding was reduced and circuit or oxygenator thrombosis was rare, using a low target aPTT [25].
For grade 4 neutropenia persisting for >7 days, a dose delay >2 weeks, grade 4 thrombocytopenia or an episode of thrombocytopenic bleeding, the dose was reduced by 20 mg m or one dose level.
The total ABR of the ODT-PT subjects was reduced by 83% to 7.3 bleeds per year with rIX-FP prophylaxis treatment (Fig. 4b).
The unit weight was reduced by approximately 1.4 times (600 kg/m3); the setting time and bleeding rate were increased by 1.5 times (73 min and 190 min) and 1.4 times (8%), respectively.
The FoxO1 protein was reduced by BBR.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com